2022 World Conference on Lung Cancer (ePosters)-EP16.04-011. Sex Hormone Signalling in Lung Adenocarcinoma Limits Tumour Virulence

Pdf Summary

Sex hormone signaling in primary lung adenocarcinoma affects tumor virulence and suggests potential therapeutic strategies, according to a study conducted by researchers from the University of Leicester and CRUK Beatson Research Institute. The study aimed to determine the expression of sex hormone receptors (SHRs) in lung adenocarcinomas and their relationship to tumor phenotypes and outcomes. The researchers found that sex hormone positivity is associated with improved survival and reduced tumor virulence, but only when engaged by appropriate hormones and in the appropriate sex. They also discovered that the co-expression of the transcription factor FOXA1 is related to SHR-associated phenotypes. The study suggests that engagement of sex hormone signaling interferes with the role of FOXA1 as a virulence factor in TTF-1 positive lung adenocarcinoma. The findings may have implications for the development of low-toxicity therapies targeting SHRs in lung adenocarcinoma. The study involved the analysis of clinical and pathological data from 1024 resected primary lung adenocarcinomas and the use of immunohistochemical assays to assess the expression of SHRs and FOXA1. The results showed that all three receptors (ER, PR, and AR) are expressed in tumors in both sexes, but ER/PR expression is beneficial in women only, while AR expression is beneficial in men only. Moreover, these sex-specific effects are dependent on the co-expression of FOXA1. Overall, the study provides new insights into the role of sex hormone signaling in lung adenocarcinoma and suggests potential personalized therapeutic approaches.

Asset Subtitle

John Le Quesne

Meta Tag

Speaker John Le Quesne

Topic Tumour Biology and Biomarkers - Tumour Biology & Preclinical Studies

Keywords

sex hormone signaling

primary lung adenocarcinoma

tumor virulence

therapeutic strategies

sex hormone receptors

tumor phenotypes

transcription factor FOXA1

improved survival

low-toxicity therapies

personalized therapeutic approaches